ArticlePharmaceutics2019
Therapeutic Potential of
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Radiation stability and performance of TEHDGA resin for theranostic scandium radionuclide purification.EJNMMI radiopharmacy and chemistry · 2026Article
- Investigating the Theranostic Potential of Elementally Matched [Molecular pharmaceutics · 2026Article
- A true theranostic pair -European journal of nuclear medicine and molecular imaging · 2026Article
- Radiolabeled Vitamins and Nanosystems as Potential Agents in Oncology Theranostics: Developed Approaches and Future Perspectives.Journal of personalized medicine · 2026Review
- The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics.Frontiers in oncology · 2026Review
- Self-illuminating liposome-derivedActa pharmaceutica Sinica. B · 2025Article
- Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy.Journal of nanobiotechnology · 2024Article
- Production of high purityEJNMMI radiopharmacy and chemistry · 2024Article
- Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlightingEJNMMI physics · 2024Article
- The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions.Frontiers in immunology · 2024Review
- Production and purification ofScientific reports · 2023Article
- Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals.Inorganic chemistry · 2023Article
- Scandium Radioisotopes-Toward New Targets and Imaging Modalities.Molecules (Basel, Switzerland) · 2023Review
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Recent Advances inInternational journal of molecular sciences · 2023Review
- Preclinical investigations using [European journal of nuclear medicine and molecular imaging · 2022Article
- Active Targeted Nanoformulations via Folate Receptors: State of the Art and Future Perspectives.Pharmaceutics · 2021Review
- Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.RSC advances · 2021Review
- Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.EJNMMI radiopharmacy and chemistry · 2021Review
- Production, Collection, and Purification ofACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 4 countries.
Funding
Abstract
Targeted radionuclide therapy with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.